;

Articles Not Curated - Drug Studies-in vitro
Last updated: 2023 Dec 18
Total hit(s): 1025
S.No.
1
38086763
Development of iminosugar-based glycosidase inhibitors as drug candidates for SARS-CoV-2 virus via molecular modelling and in vitro studies.
J Enzyme Inhib Med Chem
2024 Dec
8.6
1
2
38692139
Collection and transportation of SARS-CoV-2 and influenza A virus diagnostic samples: Optimizing the usage of guanidine-based chaotropic salts for enhanced biosafety and viral genome preservation.
Biochem Biophys Res Commun
2024 Jun 30
2.73
1
3
38652363
Deciphering the similarities and disparities of molecular mechanisms behind respiratory epithelium response to HCoV-229E and SARS-CoV-2 and drug repurposing, a systems biology approach.
Daru
2024 Jun
2.72
1
4
38708557
Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19.
J Antimicrob Chemother
2024 May 6
4.94
1
5
38668705
Detection of Active SARS-CoV-2 3CL Protease in Infected Cells Using Activity-Based Probes with a 2,6-Dichlorobenzoyloxymethyl Ketone Reactive Warhead.
ACS Chem Biol
2024 May 17
8.5
1
6
38755091
Issue 4-Impact of air pollution on COVID-19 mortality and morbidity: An epidemiological and mechanistic review.
Pulmonology
2024 May 15
0.81
1
7
38742905
Inhibition of endocytic uptake of severe acute respiratory syndrome coronavirus 2 and endo-lysosomal acidification by diphenoxylate.
Antimicrob Agents Chemother
2024 May 14
4.68
1
8
38734638
Abrogation of ORF8-IRF3 binding interface with Carbon nanotube derivatives to rescue the host immune system against SARS-CoV-2 by using molecular screening and simulation approaches.
BMC Chem
2024 May 11
1
9
38735613
The synthesis and preliminary immunological evaluation of a dual-adjuvant SARS-CoV-2 RBD vaccine: Covalent integration of TLR7/8 and iNKT cell agonists.
Int J Biol Macromol
2024 May 10
4.94
1
10
38730068
Antiviral, anti-inflammatory and antioxidant effects of curcumin and curcuminoids in SH-SY5Y cells infected by SARS-CoV-2.
Sci Rep
2024 May 10
4.12
1
11
38643719
Molecular basis of N-glycan recognition by pradimicin a and its potential as a SARS-CoV-2 entry inhibitor.
Bioorg Med Chem
2024 May 1
6.5
1
12
38550333
Investigation of phytochemicals isolated from selected Saudi medicinal plants as natural inhibitors of SARS CoV-2 main protease: In vitro, molecular docking and simulation analysis.
Saudi Pharm J
2024 May
5.6
1
13
38552631
Micro-patterned culture of iPSC-derived alveolar and airway cells distinguishes SARS-CoV-2 variants.
Stem Cell Reports
2024 Apr 9
12.2
1
14
38632023
Epidemiology and antimicrobial susceptibility profiles of Enterobacterales causing bloodstream infections before and during COVID-19 pandemic: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2018-2021.
J Microbiol Immunol Infect
2024 Apr 7
2.33
1
15
38588829
Throat spray formulated with virucidal Pharmaceutical excipients as an effective early prophylactic or treatment strategy against pharyngitis post-exposure to SARS CoV-2.
Eur J Pharm Biopharm
2024 Apr 6
1
16
38576396
Antibiotics daptomycin interacts with S protein of SARS-CoV-2 to promote cell invasion of omicron (B1.1.529) pseudovirus.
Virulence
2024 Apr 5
4.81
1
17
38604076
Evaluation of the SARS-CoV-2 RNA detection reagent LAMPdirect Genelyzer KIT using nasopharyngeal swab and saliva samples.
Diagn Microbiol Infect Dis
2024 Apr 4
2.33
1
18
38575586
The metabolic footprint of Vero E6 cells highlights the key metabolic routes associated with SARS-CoV-2 infection and response to drug combinations.
Sci Rep
2024 Apr 4
4.12
1
19
38608595
In vitro pharmacokinetic behavior in lung of harringtonine, an antagonist of SARS-CoV-2 associated proteins: New insights of inhalation therapy for COVID-19.
Phytomedicine
2024 Apr 4
7.2
1
20
38684712
A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.
Sci Rep
2024 Apr 29
4.12
1
21
38703782
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.
Lancet Microbe
2024 Apr 26
- n/a -
1
22
38677595
SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?
Antiviral Res
2024 Apr 25
4.12
1
23
38668391
SARS-CoV-2 Viral Shedding and Rapid Antigen Test Performance - Respiratory Virus Transmission Network, November 2022-May 2023.
MMWR Morb Mortal Wkly Rep
2024 Apr 25
14.4
1
24
38675980
The Dual-Targeted Fusion Inhibitor Clofazimine Binds to the S2 Segment of the SARS-CoV-2 Spike Protein.
Viruses
2024 Apr 20
3.76
1
25
38617221
Distal Protein-Protein Interactions Contribute to SARS-CoV-2 Main Protease Substrate Binding and Nirmatrelvir Resistance.
bioRxiv
2024 Apr 2
- n/a -
1